Skip to Menu Skip to Search Contact Us Skip to Content
US Flag

You are accessing SGS’s website from the USA.

Visit the US website instead

Stay on the global website and remember my choice

Cell Substrate Characterization In Vitro-based Virus Detection Methods

Regulatory authorities such as the US Food & Drug Administration (FDA) and the European Medicines Evaluation Agency (EMEA) impose stringent limits on the amount of microbial contaminates and impurities present during the manufacturing of biological medicines and vaccines.

To establish that the testing procedures are accurate, regulatory authorities require proof of testing before clinical trials can be approved or a batch of commercial biopharmaceuticals or vaccines be released. This white paper explores how all components of the manufacturing process must undergo extensive safety testing to demonstrate identity, stability and purity.

Please complete the form to download your copy.

Fields marked with an asterisk (*) are mandatory.

White paper request form

Are you an SGS client?*

200 characters remaining